OncoMatch/Clinical Trials/NCT06739226
Combination Immunotherapy Targeting Melanoma
Is NCT06739226 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Antigen-specific CAR T, CTL and DCvac to treat melanoma. for melanoma.
Treatment: Antigen-specific CAR T, CTL and DCvac to treat melanoma. — The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific antigens such as MAGE-A4, gp100 and a pool of melanoma specific antigens presented by the DCs. Another goal of the study is to learn more about the function and persistence of the CAR T cells and antigen-specific immune effectors in patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: standard first-line therapy
Patients with melanoma have received standard first-line therapy
Cannot have received: genetically engineered CAR T cells
Previous treatment with other genetically engineered CAR T cells.
Lab requirements
Blood counts
white blood cell count ≥1000/ul, absolute neutrophil count ≥500/ul, absolute lymphocyte count ≥500/ul, platelet count ≥25,000/ul (not achieved by transfusion)
Kidney function
serum creatinine less than 3 times uln
Liver function
alt <3x uln, ast <3x uln; serum bilirubin and alkaline phosphatase <2x uln
Cardiac function
left ventricular ejection fraction greater than or equal to 40/55 percent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06739226 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior genetically engineered CAR T cells disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages